The business club reported on July 1 that Chinese patent medicines are in disappointment in the EU, and plant extracts are promising. Yesterday, the first seminar on the internationalization of extracts of traditional Chinese medicines and plant herbs was held in Han. All participants in the conference called for the formulation of internationally unified standards for plant extracts in China as soon as possible to meet the needs of the international market.
The symposium was hosted by the Chinese Medical Quality Standards Professional Committee, Wuhan Optical Valley Biological City, etc. The research institutes and trade associations from the Chinese medicine and plant extracts industries participated in the seminar.
It is reported that plant extracts are active ingredient-containing substances extracted from natural plants. Plant extracts are the main raw materials of plant medicines and can be applied to nutritional supplements, health foods, cosmetics, etc. They are the core products of the natural medicine and health products market.
According to statistics, plant extracts are the main force for the export of traditional Chinese medicines in China. Last year, China’s exports in this area rose to 801.5 billion US dollars, accounting for 41.92% of the total exports of Chinese medicines. After the European Union's "Registration Procedure for Traditional Plant Drugs" 7-year transition period ended on April 30 this year, due to the unsuccessful registration of Chinese proprietary Chinese medicines, proprietary Chinese medicines will leave the European Union. The industry believes that the EU market as a large market for plant medicine, Chinese medicine disappointed or will create an opportunity for plant extracts.
At present, there are more than 100 kinds of plant extracts produced in China, of which the plant extracts that have been produced on a large scale and exported include Ginkgo biloba extract, green tea extract, and ginseng extract. These products have a large market share in Western countries.
As an emerging industry, most of the plant extracts in China lack uniform standards. According to Liu Zhanglin, vice president of the China Chamber of Commerce for the Import and Export of Medicines and Health Products, our manufacturing companies have always followed the customer's standards, that is, produced according to customer requirements. Although the operation is simple, the disadvantages are obvious: once the customer raises objections to the quality of the product, the production company will be subject to the people, and many companies have already suffered losses and suffered losses.
At the seminar yesterday, a number of experts appealed that China must establish a unified international standard as soon as possible, and adopt advanced inspection and testing techniques and methods in accordance with international standards to establish a sound and standardized industry standard system for more varieties of plant extracts. . (Chinese patent medicine is frustrated in the EU, and plant extracts have a bright future. Yesterday, the first seminar on the internationalization of extracts of traditional Chinese medicine and botanical drugs was held in Han. The participants from all walks of life called for the formulation of an international unified standard for plant extracts in China as soon as possible. Adapt to the needs of the international market.
The symposium was hosted by the Chinese Medical Quality Standards Professional Committee, Wuhan Optical Valley Biological City, etc. The research institutes and trade associations from the Chinese medicine and plant extracts industries participated in the seminar.
It is reported that plant extracts are active ingredient-containing substances extracted from natural plants. Plant extracts are the main raw materials of plant medicines and can be applied to nutritional supplements, health foods, cosmetics, etc. They are the core products of the natural medicine and health products market.
According to statistics, plant extracts are the main force for the export of traditional Chinese medicines in China. Last year, China’s exports in this area rose to 801.5 billion US dollars, accounting for 41.92% of the total exports of Chinese medicines. After the European Union's "Registration Procedure for Traditional Plant Drugs" 7-year transition period ended on April 30 this year, due to the unsuccessful registration of Chinese proprietary Chinese medicines, proprietary Chinese medicines will leave the European Union. The industry believes that the EU market as a large market for plant medicine, Chinese medicine disappointed or will create an opportunity for plant extracts.
At present, there are more than 100 kinds of plant extracts produced in China, of which the plant extracts that have been produced on a large scale and exported include Ginkgo biloba extract, green tea extract, and ginseng extract. These products have a large market share in Western countries.
As an emerging industry, most of the plant extracts in China lack uniform standards. According to Liu Zhanglin, vice president of the China Chamber of Commerce for the Import and Export of Medicines and Health Products, our manufacturing companies have always followed the customer's standards, that is, produced according to customer requirements. Although the operation is simple, the disadvantages are obvious: once the customer raises objections to the quality of the product, the production company will be subject to the people, and many companies have already suffered losses and suffered losses.
At the seminar yesterday, a number of experts appealed that China must establish a unified international standard as soon as possible, and adopt advanced inspection and testing techniques and methods in accordance with international standards to establish a sound and standardized industry standard system for more varieties of plant extracts. . (Jiang Hui Guo Shaoyan Luo Zhi)
The symposium was hosted by the Chinese Medical Quality Standards Professional Committee, Wuhan Optical Valley Biological City, etc. The research institutes and trade associations from the Chinese medicine and plant extracts industries participated in the seminar.
It is reported that plant extracts are active ingredient-containing substances extracted from natural plants. Plant extracts are the main raw materials of plant medicines and can be applied to nutritional supplements, health foods, cosmetics, etc. They are the core products of the natural medicine and health products market.
According to statistics, plant extracts are the main force for the export of traditional Chinese medicines in China. Last year, China’s exports in this area rose to 801.5 billion US dollars, accounting for 41.92% of the total exports of Chinese medicines. After the European Union's "Registration Procedure for Traditional Plant Drugs" 7-year transition period ended on April 30 this year, due to the unsuccessful registration of Chinese proprietary Chinese medicines, proprietary Chinese medicines will leave the European Union. The industry believes that the EU market as a large market for plant medicine, Chinese medicine disappointed or will create an opportunity for plant extracts.
At present, there are more than 100 kinds of plant extracts produced in China, of which the plant extracts that have been produced on a large scale and exported include Ginkgo biloba extract, green tea extract, and ginseng extract. These products have a large market share in Western countries.
As an emerging industry, most of the plant extracts in China lack uniform standards. According to Liu Zhanglin, vice president of the China Chamber of Commerce for the Import and Export of Medicines and Health Products, our manufacturing companies have always followed the customer's standards, that is, produced according to customer requirements. Although the operation is simple, the disadvantages are obvious: once the customer raises objections to the quality of the product, the production company will be subject to the people, and many companies have already suffered losses and suffered losses.
At the seminar yesterday, a number of experts appealed that China must establish a unified international standard as soon as possible, and adopt advanced inspection and testing techniques and methods in accordance with international standards to establish a sound and standardized industry standard system for more varieties of plant extracts. . (Chinese patent medicine is frustrated in the EU, and plant extracts have a bright future. Yesterday, the first seminar on the internationalization of extracts of traditional Chinese medicine and botanical drugs was held in Han. The participants from all walks of life called for the formulation of an international unified standard for plant extracts in China as soon as possible. Adapt to the needs of the international market.
The symposium was hosted by the Chinese Medical Quality Standards Professional Committee, Wuhan Optical Valley Biological City, etc. The research institutes and trade associations from the Chinese medicine and plant extracts industries participated in the seminar.
It is reported that plant extracts are active ingredient-containing substances extracted from natural plants. Plant extracts are the main raw materials of plant medicines and can be applied to nutritional supplements, health foods, cosmetics, etc. They are the core products of the natural medicine and health products market.
According to statistics, plant extracts are the main force for the export of traditional Chinese medicines in China. Last year, China’s exports in this area rose to 801.5 billion US dollars, accounting for 41.92% of the total exports of Chinese medicines. After the European Union's "Registration Procedure for Traditional Plant Drugs" 7-year transition period ended on April 30 this year, due to the unsuccessful registration of Chinese proprietary Chinese medicines, proprietary Chinese medicines will leave the European Union. The industry believes that the EU market as a large market for plant medicine, Chinese medicine disappointed or will create an opportunity for plant extracts.
At present, there are more than 100 kinds of plant extracts produced in China, of which the plant extracts that have been produced on a large scale and exported include Ginkgo biloba extract, green tea extract, and ginseng extract. These products have a large market share in Western countries.
As an emerging industry, most of the plant extracts in China lack uniform standards. According to Liu Zhanglin, vice president of the China Chamber of Commerce for the Import and Export of Medicines and Health Products, our manufacturing companies have always followed the customer's standards, that is, produced according to customer requirements. Although the operation is simple, the disadvantages are obvious: once the customer raises objections to the quality of the product, the production company will be subject to the people, and many companies have already suffered losses and suffered losses.
At the seminar yesterday, a number of experts appealed that China must establish a unified international standard as soon as possible, and adopt advanced inspection and testing techniques and methods in accordance with international standards to establish a sound and standardized industry standard system for more varieties of plant extracts. . (Jiang Hui Guo Shaoyan Luo Zhi)
The so-called pharmaceutical intermediates are actually some chemical raw materials or chemical products used in the pharmaceutical synthesis process. This chemical product does not require a production license for medicines, and can be produced in ordinary chemical plants. As long as it reaches a certain level, it can be used for the synthesis of medicines.
Explanation: Some chemicals used in drug synthesis
Purpose: Synthesis of medicines
Features: low profitability of production intermediates
Representative: fluorine-containing pyridines, etc.
Field: Medicine
Anti-Influenza Drugs,Api Oseltamivir Phosphate,Intermediate For Oseltamivir Phosphate,Vortioxetine Hydrobromide Intermediate
Jinan Prosperity International Trade Co. Ltd , https://www.jnprosperity.com